Inhibition of PARP-1 is an emerging therapeutic target in cancer therapy [138], thus its activation by the reduction in cellular nicotinamide levels by NNMT may contribute to the pro-oncogenic effect of PARP-1. This evidence concerns the gene PARP1 and cancer.